PMC:7309518 / 2099-2606 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T36","span":{"begin":156,"end":164},"obj":"Disease"},{"id":"T37","span":{"begin":186,"end":189},"obj":"Disease"},{"id":"T38","span":{"begin":211,"end":232},"obj":"Disease"},{"id":"T39","span":{"begin":310,"end":318},"obj":"Disease"},{"id":"T40","span":{"begin":319,"end":328},"obj":"Disease"},{"id":"T41","span":{"begin":470,"end":491},"obj":"Disease"}],"attributes":[{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"}],"text":"complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on commo"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":346,"end":353},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on commo"}

{"project":"LitCovid-PubTator","denotations":[{"id":"86","span":{"begin":378,"end":386},"obj":"Species"},{"id":"87","span":{"begin":445,"end":453},"obj":"Species"},{"id":"88","span":{"begin":156,"end":164},"obj":"Disease"},{"id":"89","span":{"begin":200,"end":232},"obj":"Disease"},{"id":"90","span":{"begin":310,"end":318},"obj":"Disease"},{"id":"91","span":{"begin":319,"end":328},"obj":"Disease"},{"id":"92","span":{"begin":459,"end":491},"obj":"Disease"}],"attributes":[{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"Tax:9606"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"Tax:9606"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"MESH:C000657245"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:D020274"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"MESH:C000657245"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"MESH:D007239"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:D020274"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on commo"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":14,"end":29},"obj":"http://purl.obolibrary.org/obo/GO_0045087"}],"text":"complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on commo"}

{"project":"LitCovid-sentences","denotations":[{"id":"T17","span":{"begin":116,"end":127},"obj":"Sentence"},{"id":"T18","span":{"begin":128,"end":300},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on commo"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T18","span":{"begin":405,"end":417},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002960"}],"text":"complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on commo"}